Home > Publications Database > Subthalamic nucleus deep brain stimulation induces nigrostriatal dopaminergic plasticity in a stable rat model of Parkinson's disease. > print

001     258243
005     20231004134645.0
024 7 _ |a 10.1097/WNR.0000000000001917
|2 doi
024 7 _ |a pmid:37270842
|2 pmid
024 7 _ |a pmc:PMC10234325
|2 pmc
024 7 _ |a 0959-4965
|2 ISSN
024 7 _ |a 1473-558X
|2 ISSN
024 7 _ |a altmetric:149549112
|2 altmetric
037 _ _ |a DZNE-2023-00589
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Helf, Charlotte
|b 0
245 _ _ |a Subthalamic nucleus deep brain stimulation induces nigrostriatal dopaminergic plasticity in a stable rat model of Parkinson's disease.
260 _ _ |a [Erscheinungsort nicht ermittelbar]
|c 2023
|b Ovid
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1687785893_14543
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been a highly effective treatment option for middle to late stage Parkinson's disease for decades. Though, the underlying mechanisms of action, particularly effects on the cellular level, remain in part unclear. In the context of identifying disease-modifying effects of STN-DBS by prompting cellular plasticity in midbrain dopaminergic systems, we analyzed neuronal tyrosine hydroxylase and c-Fos expression in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA).We applied 1 week of continuous unilateral STN-DBS in a group of stable 6-hydroxydopamine (6-OHDA) hemiparkinsonian rats (STNSTIM) in comparison to a 6-OHDA control group (STNSHAM). Immunohistochemistry identified NeuN+, tyrosine hydroxylase+ and c-Fos+ cells within the SNpc and VTA.After 1 week, rats in the STNSTIM group had 3.5-fold more tyrosine hydroxylase+ neurons within the SNpc (P = 0.010) but not in the VTA compared to sham controls. There was no difference in basal cell activity as indicated by c-Fos expression in both midbrain dopaminergic systems.Our data support a neurorestorative effect of STN-DBS in the nigrostriatal dopaminergic system already after 7 days of continuous STN-DBS in the stable Parkinson's disease rat model without affecting basal cell activity.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Oxidopamine
|0 8HW4YBZ748
|2 NLM Chemicals
650 _ 7 |a Tyrosine 3-Monooxygenase
|0 EC 1.14.16.2
|2 NLM Chemicals
650 _ 7 |a Dopamine
|0 VTD58H1Z2X
|2 NLM Chemicals
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Parkinson Disease: therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Subthalamic Nucleus: metabolism
|2 MeSH
650 _ 2 |a Oxidopamine: toxicity
|2 MeSH
650 _ 2 |a Deep Brain Stimulation
|2 MeSH
650 _ 2 |a Tyrosine 3-Monooxygenase: metabolism
|2 MeSH
650 _ 2 |a Dopamine: metabolism
|2 MeSH
650 _ 2 |a Substantia Nigra: metabolism
|2 MeSH
700 1 _ |a Kober, Maria
|b 1
700 1 _ |a Markert, Franz
|b 2
700 1 _ |a Lanto, Jennifer
|b 3
700 1 _ |a Overhoff, Leonie
|b 4
700 1 _ |a Badstübner-Meeske, Kathrin
|b 5
700 1 _ |a Storch, Alexander
|0 P:(DE-2719)9000306
|b 6
|u dzne
700 1 _ |a Fauser, Mareike
|b 7
773 _ _ |a 10.1097/WNR.0000000000001917
|g Vol. 34, no. 10, p. 506 - 511
|0 PERI:(DE-600)2031485-1
|n 10
|p 506 - 511
|t Neuroreport
|v 34
|y 2023
|x 0959-4965
856 4 _ |u https://journals.lww.com/neuroreport/Fulltext/2023/06020/Subthalamic_nucleus_deep_brain_stimulation_induces.3.aspx
856 4 _ |u https://pub.dzne.de/record/258243/files/DZNE-2023-00589.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/258243/files/DZNE-2023-00589.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:258243
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000306
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-09
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-09
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2023-08-22
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROREPORT : 2022
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-22
920 1 _ |0 I:(DE-2719)5000014
|k AG Storch 2 Rostock
|l Non-Motor Symptoms in Parkinson's disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000014
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21